Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions
Authors
Keywords
-
Journal
Cancer Medicine
Volume 10, Issue 9, Pages 3035-3044
Publisher
Wiley
Online
2021-04-01
DOI
10.1002/cam4.3867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
- (2019) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients
- (2019) Hugo J.A. Adams et al. ANNALS OF HEMATOLOGY
- Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis
- (2018) Coreline N. Burggraaff et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
- (2017) Sally F. Barrington et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis
- (2016) Hugo J.A. Adams et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis
- (2016) Hugo J.A. Adams et al. EUROPEAN JOURNAL OF RADIOLOGY
- Diffuse Large B-Cell Lymphoma Version 1.2016
- (2016) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas
- (2016) Sally F. Barrington et al. Current Hematologic Malignancy Reports
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy
- (2015) Dai Chihara et al. Expert Review of Anticancer Therapy
- Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
- (2015) Christoph Mamot et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
- (2015) Rosalba Camicia et al. Molecular Cancer
- Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy
- (2014) Jordina Rovira et al. ANNALS OF HEMATOLOGY
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) H. Tilly et al. ANNALS OF ONCOLOGY
- Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
- (2012) P. Pregno et al. BLOOD
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Role of Functional Imaging in the Management of Lymphoma
- (2011) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
- (2010) Craig H. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started